We are delighted to announce that our CEO will be presenting at the Neoantigen-Based Therapies Summit 2022 hosted by Hanson Wade in Boston from October 24-26th! He will be presenting PDC*line Pharma...
Preliminary results with PDC*lung01 in monotherapy and at low dose with pembrolizumab evoke acceptable safety profile, immunological activity and promising tumor response in Non-Small Cell Lung Cancer...
We are thrilled to announce that PDC*line Pharma will be presenting a poster at the ESMO - European Society for Medical Oncology Annual Meeting 2022 taking place from 9 to 13 September 2022, in Paris...
Very are delighted to announce that our CEO Eric Halioua will chair a panel April 28th at the 5th Neoantigen Summit Europe organized by Hanso Wade in Amsterdam, Netherlands from April 26th to April...
We are delighted to announce of the publication by our CSO Joël Plumas of a new review article in scientific journal Current Opinion in Oncology and intitled "Harnessing dendritic cells for innovative...
PDC*line Pharma raises €17.5 million ($20,3M) in Series B2 financing round
New funding includes €11.8M in equity and €5.7M in grants. It completes the €20M B1 round of financing announced in January...
B2 cohort (high dose added to anti-PD-1) of the PDC-LUNG-101 trial with PDC*lung01 therapeutic cancer vaccine candidate for non-small cell lung cancer has been opened and first patients were dosed
...
It has been a pleasure and an honor for our CEO Eric Halioua to participate Friday October 8th as a speaker at the EU-Korea Global Vaccine partnership roundtable with Mr Han-koo Yeo, Minister for...
Available now for replay, the interview of PDC*line Pharma 's President & CEO Eric Halioua by journalist of the program « Itinéraires santé » in the TV studio of the French Media group Le Figaro.
In...
